Бикалутамид Тева 150 мг

Pays: Israël

Langue: russe

Source: Ministry of Health

Ingrédients actifs:

BICALUTAMIDE 150 MG

Disponible depuis:

TEVA PHARMACEUTICAL INDUST.LTD

Code ATC:

L02BB03

forme pharmaceutique:

TABLETS

Mode d'administration:

PER OS

Fabriqué par:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Groupe thérapeutique:

BICALUTAMIDE

indications thérapeutiques:

In patients with locally advanced prostate cancer (T3-T4 any N M0 T1-T2 N+ M0) Bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. The management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Date de l'autorisation:

2009-05-01